Skip to main content
TipRanks
Go Ultimate75% OFF

NervGen Pharma (9UA) Stock Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

9UA Analyst Ratings

Moderate Buy
1Ratings
1Buy0Hold0Sell
Based on 1 analysts giving stock ratings to NervGen Pharma in the past 3 months

9UA Stock 12 Month Forecast

€9.07▲(446.48% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for NervGen Pharma in the last 3 months. The average price target is EUR 9.07 with a high forecast of EUR 9.07 and a low forecast of EUR 9.07. The average price target represents a 446.48% change from the last price of EUR 1.66.
Highest Price Target€9.07Average Price Target€9.07Lowest Price Target€9.07

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for DE:9UA
Price TargetArticle
Leerink Partners€9.07buy446.48%UpsideReiterated10/01/26
TD Cowen―buy―Reiterated08/13/26
H.C. Wainwright€16.33→€13.61buy719.71%UpsideReiterated07/14/26
Stifel Nicolaus€5.44buy227.89%UpsideReiterated05/21/26
Lucid Capital€16.33buy883.66%UpsideInitiated04/15/26
Research Capital€4.99buy200.56%UpsideReiterated04/10/26
Maxim Group€9.07→€10.89buy555.77%UpsideAssigned04/09/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PLSEPulse Biosciences
SLDBSolid Biosciences
RZLTRezolute
IMUXImmunic
MDWDMediwound

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering NervGen Pharma

3 Months
Justin Keywood
Justin KeywoodStifel Nicolaus
Success Rate4/11 ratings generated profit
36%
Average Return
-11.20%

Copying Justin Keywood's trades and holding each position for 3 Months would result in 36.36% of your transactions generating a profit, with an average return of -11.20% per trade.

1 Year
Justin Keywood
Justin KeywoodStifel Nicolaus
Success Rate6/11 ratings generated profit
55%
Average Return
+9.51%

Copying Justin Keywood's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +9.51% per trade.

2 Years
Justin Keywood
Justin KeywoodStifel Nicolaus
Success Rate2/11 ratings generated profit
18%
Average Return
-7.85%

Copying Justin Keywood's trades and holding each position for 2 Years would result in 18.18% of your transactions generating a profit, with an average return of -7.85% per trade.

9UA Analyst Recommendation Trends

05101520Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for 9UA
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy54211
Buy12110
Hold00000
Sell00000
Strong Sell00000
total66321

In the current month, 9UA has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 9UA average Analyst price target in the past 3 months is 9.07.

9UA Financial Forecast

€-2€-1.5€-1€-0.5€0Q4 2025Q3 2026Q4 2026
High€-0.09
Consensus€-0.11
Low€-0.13

9UA Earnings Forecast

Next quarter’s earnings estimate for 9UA is -EUR 0.11 with a range of -EUR 0.13 to -EUR 0.09. The previous quarter’s EPS was -EUR 0.04. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

€-1€-0.5€0€0.5€1Q4 2025Q3 2026Q4 2026
High€0.00
Consensus€0.00
Low€0.00

9UA Sales Forecast

Next quarter’s sales forecast for 9UA is EUR 0 with a range of EUR 0 to EUR 0. The previous quarter’s sales results were ―. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

9UA Stock Forecast FAQ

What is DE:9UA’s average 12-month price target, according to analysts?
Based on analyst ratings, NervGen Pharma’s 12-month average price target is €9.07.
What is DE:9UA’s upside potential, based on the analysts’ average price target?
NervGen Pharma has 446.48% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NervGen Pharma a Buy, Sell or Hold?
NervGen Pharma has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is NervGen Pharma’s share price target?
The average share price target for NervGen Pharma is €9.07. This is based on 1 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €9.07, and the lowest forecast is €9.07. The average share price target represents a 446.48% increase from the current price of €1.66.
What do analysts say about NervGen Pharma?
NervGen Pharma’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Street analysts.
How can I buy shares of NervGen Pharma?
To buy shares of DE:9UA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.